Table 2.

Characteristics of 549 female patients diagnosed between 2005 and 2011 with a RS of 11–25 by receipt of chemotherapy

	Chemotherapy		No chemotherapy		p-value
	(N= 92)		(N= 457)
	N	(%)	N	(%)
Age at diagnosis, years
20 – 40	15	16.3%	24	5.3%	p<0.001
41 – 50	37	40.2%	113	24.7%
51 – 60	23	25%	158	34.6%
61 – 70	13	14.1%	136	29.8%
71 and above	4	4.4%	26	5.7%
Median (Q1–Q3)	50 (44–57)		57 (49–63)		p<0.001
Race/Ethnicity
Caucasian	70	76.1%	346	75.7%	0.652
African-American	7	7.6%	23	5.0%
Hispanic	9	9.8%	60	13.1%
Other	6	6.5%	28	6.1%
Menopausal Status
Post	52	56.5%	329	72.0%	0.010
Pre	36	39.1%	119	26.0%
Perimenopausal/Unknown	4	4.4%	9	2.0%
Histology
Ductal	69	75.0%	331	72.4%	0.571
Lobular	10	10.9%	65	14.2%
Mixed	10	10.9%	37	8.1%
Other	3	3.3%	24	5.3%
Nuclear Grade
I	11	12.0%	65	14.2%	0.727
II	64	69.6%	320	70.0%
III	17	18.5%	72	15.8%
Ki-67 expression†
Median (range)	10 (1 – 60)		10 (0 – 88)		0.689
>14%	23	41.1%	99	39.4%	0.822
Lymphovascular invasion‡	14	15.2%	50	11.1%	0.250
Tumor Stage
I	64	69.6%	367	80.3%	0.02
II	28	30.4%	90	19.7%
Tumor size (cm)
< 1.0	12	13.0%	103	22.5%	0.050
1.1 – 1.9	45	48.9%	234	51.2%
2.0 – 2.9	22	23.9%	78	17.1%
3.0 – 3.9	8	8.7%	17	3.7%
≥ 4.0	5	5.4%	25	5.5%
Median (Q1–Q3)	1.5 (1.2–2.2)		1.4 (1.0–2.0)		0.052
Surgery type
Partial mastectomy	56	60.9%	280	61.3%	0.943
Mastectomy	36	39.1%	177	38.7%
Radiation therapy	53	57.6%	274	60.0%	0.676
Endocrine therapy	90	97.8%	436	95.4%	0.290

^†Available for 307 patients

^‡Available for 547 patients